Why Clearmind Stock Is Climbing Higher Tuesday

Clearmind Medicine Inc (NYSE:CMND) shares are trading higher Tuesday after the company announced results in its cocaine addiction treatment.

What Happened: Clearmind said it achieved positive results in addiction treatment testing of the company's innovative psychedelic molecule MEAI. 

Clearmind filed a patent application related to cocaine addiction following the company's collaboration testing with SciSparc's CannAmide.

"Our unique psychedelic compound has shown remarkable results in pre-clinical trials for cocaine addiction," said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine.

"These promising results from our MEAI-based treatment offer a potential paradigm shift in how we approach the complex challenge of cocaine addiction, an addiction for which no dedicated treatment has yet been developed."

Clearmind is a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems.

See Also: What's Going On With Sidus Space Stock Today?

CMND Price Action: Clearmind shares were up 66.9% at $6.42 at the time of publication, according to Benzinga Pro.

Photo: Pexels from Pixabay.